• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Healthcare IT Regulations – What Needs to Be Added and What Needs to Be Removed
There are a lot of rules and regulations in place in the world of healthcare. These are put into place in order to protect patients and organizations. However, the world of healthcare is constantly changing and evolving as we come up with new ideas and solutions. Have the regulations done the same though? Or are there areas that are missing regulations? Or are there areas in healthcare where past regulations are now too restrictive and are holding us back? In search of answers to these questions, we reached out to our incredibly beautiful Healthcare IT Today Community to see what areas they would add, remove, or update re...
Source: EMR and HIPAA - September 19, 2023 Category: Information Technology Authors: Grayson Miller Tags: Administration Ambulatory C-Suite Leadership Health IT Company Healthcare IT Hospital - Health System LTPAC Regulations 1upHealth 4medica Amanda Heidemann Andrea Mazzoccoli Andrew Norden MD Bill Charnetski Cheryl Cheng Commur Source Type: blogs

Gender-Based Research Underscores Sex Differences in Biological Processes, Clinical Disorders and Pharmacological Interventions
Biochem Pharmacol. 2023 Aug 5:115737. doi: 10.1016/j.bcp.2023.115737. Online ahead of print.ABSTRACTEarlier research has presumed that the male and female biology is similar in most organs except the reproductive system, leading to major misconceptions in research interpretations and clinical implications, with serious disorders being overlooked or misdiagnosed. Careful research has now identified sex differences in the cardiovascular, renal, endocrine, gastrointestinal, immune, nervous, and musculoskeletal systems. Also, several cardiovascular, immunological, and neurological disorders have shown differences in prevalence...
Source: Biochemical Pharmacology - August 7, 2023 Category: Drugs & Pharmacology Authors: Sofia R Bernstein Caroline Kelleher Raouf A Khalil Source Type: research

Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021)
This study is registered with ClinicalTrials.gov, NCT03170960.FINDINGS: Between April 24, 2018, and Aug 31, 2020, 132 patients were enrolled and received at least one dose of study treatment. At data cutoff (Feb 19, 2021), median duration of follow-up was 15·2 months (IQR 9·6-21·7). Objective response rate was 23% (95% CI 17-32; 31 of 132 patients), with three (2%) confirmed complete responses and 28 (21%) confirmed partial responses. 72 (55%) of 132 patients had grade 3-4 treatment-related adverse events, with the most common being pulmonary embolism (11 [8%] patients), diarrhoea (nine [7%]), fatigue (nine [7%]), and h...
Source: Ann Oncol - June 11, 2022 Category: Cancer & Oncology Authors: Neeraj Agarwal Bradley McGregor Benjamin L Maughan Tanya B Dorff William Kelly Bruno Fang Rana R McKay Parminder Singh Lance Pagliaro Robert Dreicer Sandy Srinivas Yohann Loriot Ulka Vaishampayan Sanjay Goel Dominic Curran Ashok Panneerselvam Martin Schwi Source Type: research

Fight Aging! Newsletter, December 6th 2021
In this study, they found these drugs can kill senescent cells from cultures of human fat tissue. The tissue was donated by individuals with obesity who were known to have metabolic troubles. Without treatment, the human fat tissues induced metabolic problems in immune-deficient mice. After treatment with dasatinib and quercetin, the harmful effects of the fat tissue were almost eliminated. Targeting p21Cip1 highly expressing cells in adipose tissue alleviates insulin resistance in obesity Insulin resistance is a pathological state often associated with obesity, representing a major risk factor for type 2...
Source: Fight Aging! - December 5, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

Fight Aging! Newsletter, January 4th 2021
The objective of this study is to quantify the overall and cancer type-specific risks of subsequent primary cancers (SPCs) among adult-onset cancer survivors by first primary cancer (FPC) types and sex. Among 1,537,101 survivors (mean age, 60.4 years; 48.8% women), 156,442 SPC cases and 88,818 SPC deaths occurred during 11,197,890 person-years of follow-up (mean, 7.3 years). Among men, the overall risk of developing any SPCs was statistically significantly higher for 18 of the 30 FPC types, and risk of dying from any SPCs was statistically significantly higher for 27 of 30 FPC types as compared with risks in the general po...
Source: Fight Aging! - January 3, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs

A Look Back at 2020: Progress Towards the Treatment of Aging as a Medical Condition
While I suspect that COVID-19 will feature prominently in most retrospectives on 2020, I'll say only a little on it. The data on mortality by year end, if taken at face value, continues to suggest that the outcome will fall at the higher end of the early estimates of a pandemic three to six times worse than a bad influenza year, ten times worse than a normal influenza year. The people who die are near entirely the old, the co-morbid, and the immunocompromised. They die because they are suffering the damage and dysfunction of aging. Yet the societal conversation and the actions of policy makers ignore this. There is ...
Source: Fight Aging! - December 31, 2020 Category: Research Authors: Reason Tags: Of Interest Source Type: blogs